SLF
ESPR icon

Sun Life Financial’s Esperion Therapeutics ESPR Stock Holding History

Sun Life Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,364
Closed -$197K – 495
2019
Q3 		$197K Buy
+5,364
New +$212K 0.05% 181

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Sun Life Financial's ESPR Position: Q4 2019 in Review

Sun Life Financial sold out of Esperion Therapeutics (ESPR) in Q4 2019, closing a stake of 5,364 shares — an estimated $197K sold.

Sun Life Financial first reported a position in ESPR in Q3 2019 and held it in 1 quarter. The position peaked at $197K in Q3 2019. 172 funds tracked by Wall St. Rank hold ESPR as of Q4 2019.

  • Sun Life Financial reported no remaining Esperion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sun Life Financial sold 5,364 Esperion Therapeutics shares in Q4 2019, an estimated $197K.
  • Sun Life Financial first reported a position in Esperion Therapeutics in Q3 2019 and held it in 1 quarter.
  • Sun Life Financial's Esperion Therapeutics position peaked at $197K in Q3 2019.
  • 172 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.